Google
TYRA — TYRA BIOSCIENCES INC (Healthcare >> Biotechnology)
TYRA FAQ
What is TYRA's ROE?
TYRA BIOSCIENCES INC reports a Return on Equity (ROE) of -33.83%.
What is TYRA's dividend yield?
TYRA BIOSCIENCES INC offers a dividend yield of 0.00%.
What is TYRA's Deepscope Quality Score?
Deepscope rates TYRA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TYRA?
Deepscope's AI Timing Score for TYRA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TYRA belong to?
TYRA BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 28.69
Price
0.03
(0.10%)
Day Change
|
|
|---|
TYRA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 28.69 |
| PBV / Sector |
4.40 / 4.48
|
| Earning Per Share | -2.21 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
23.51 M
GREAT
|
| Average 1W Daily Value |
25.51 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:06 |
| Symbol | TYRA |
| Name | TYRA BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.47 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,704.42 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2656 State Street, Carlsbad, CA, United States, 92008
Phone: 619 728 4760
Website: https://tyra.bio
Employees: 87
Sector: Healthcare >> Biotechnology
Description: Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
